Antibodies to watch in 2023

References

• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. doi:10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476. doi:10.1080/19420862.2020.1860476.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12(1):1703531. doi:10.1080/19420862.2019.1703531.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–42. doi:10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10(2):183–203. doi:10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9(2):167–81. doi:10.1080/19420862.2016.1269580.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8(2):197–204. doi:10.1080/19420862.2015.1125583.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8. doi:10.4161/19420862.2015.988944.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014. MAbs. 2014;6(1):5–14. doi:10.4161/mabs.27333.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs. 2013;5(1):1–4. doi:10.4161/mabs.22976.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2012? MAbs. 2012;4(1):1–3. doi:10.4161/mabs.4.1.18719.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76–99. doi:10.4161/mabs.3.1.13895.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs. 2010;2(1):84–100. doi:10.4161/mabs.2.1.10677.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Emergency Use Authorization. [accessed 2022 Nov 19]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
   Google Scholar
• Wang Q, Li Z, Ho J, Guo Y, Yanchen A, Liu M, Wang M, Yu J, Sheng Z, Huang Y, et al. Resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralization. bioRxiv preprint posted September 6, 2022 accessed 2022 September 6.10.1101/2022.09.05.506628
   Google Scholar
• InflaRx NV InflaRx submits request for Emergency Use Authorization to US FDA for vilobelimab for treatment of critically ill COVID-19 patients. September 29, 2022 press release [accessed 2022 Nov 12]. https://www.inflarx.de/Home/Investors/Press-Releases/09-2022-InflaRx-Submits-Request-for-Emergency-Use-Authorization-to-US-FDA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-.html.
   Google Scholar
• The Antibody Society, Inc. Antibody therapeutics approved or in regulatory review in the EU or US. [accessed 2022 Nov 18]. https://www.antibodysociety.org/resources/approved-antibodies/.
   Google Scholar
• Immunocore Holdings pl. Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma. January 26, 2022, press release [accessed 2022 August 25]. https://ir.immunocore.com/news-releases/news-release-details/immunocore-announces-fda-approval-kimmtrakr-tebentafusp-tebn.
   Google Scholar
• Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206. doi:10.1056/NEJMoa2103485.
   PubMed Web of Science ®Google Scholar
• Genentech. FDA approves Genentech’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss. January 28, 2022, press release [accessed 2022 Aug 23]. https://www.gene.com/media/press-releases/14943/2022-01-28/fda-approves-genentechs-vabysmo-the-firs.
   Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–40. doi:10.1016/S0140-6736(22)00010-1.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two andomized, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–55. doi:10.1016/S0140-6736(22)00018-6.
   PubMed Web of Science ®Google Scholar
• Genentech. New two-year data confirm Genentech’s Vabysmo improves vision with fewer treatments for people with wet-age-related macular degeneration. July 14, 2022, press release [accessed 2022 Aug 23]. https://www.gene.com/media/press-releases/14960/2022-07-14/new-two-year-data-confirm-genentechs-vab.
   Google Scholar
• Sanofi. FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. February 4, 2022, press release [accessed 2022 Aug 23]. https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-04-22-00-00-2379517.
   Google Scholar
• Sanofi. European commission approves enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease. Nov 17, 2022 press release [accessed 2022 Nov 18]. https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-17-17-50-00-2558583.
   Google Scholar
• Röth A, Berentsen S, Barcellini W, D’Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura J-I, Vos JMI, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;blood.2021014955. doi:10.1182/blood.2021014955.
   PubMedGoogle Scholar
• Bristol Myers Squibb US Food and Drug Administration approves first LAG-3-blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma. March 18, 2022, press release [accessed 2022 Aug 23]. https://news.bms.com/news/corporate-financial/2022/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspx.
   Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMoa2109970.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. December 8, 2021 press release [accessed 2022 Aug 29]. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html.
   Google Scholar
• U.S. Food and Drug Administration. FDA authorizes revisions to Evusheld dosing. June 29, 2022 [accessed 2022 Aug 30]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing.
   Google Scholar
• AstraZeneca. AstraZeneca’s antibody combination, Evusheld (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19. March 17, 2022 [accessed 2022 Aug 30] https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html.
   Google Scholar
• AstraZeneca. Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19. March 24, 2022 [2022 Aug 30] https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19.html.
   Google Scholar
• AstraZeneca. Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan. August 30, 2022 press release [accessed 2022 Aug 30]. https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html#!.
   Google Scholar
• Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seth Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Resp Med. 2022;10(10):985–96. doi:10.1016/S2213-2600(22)00180-1.
   PubMed Web of Science ®Google Scholar
• Roche. European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma. June 8, 2022, press release [accessed 2022 Aug 30]. https://www.roche.com/media/releases/med-cor-2022-06-08.
   Google Scholar
• Genentech. FDA grants priority review to Genentech’s mosunetuzumab for people with relapsed or refractory follicular lymphoma. July 5, 2022, press release [accessed 2022 Aug 30]. https://www.gene.com/media/press-releases/14958/2022-07-05/fda-grants-priority-review-to-genentechs.
   Google Scholar
• The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen marks first approval worldwide for TECVAYLI® (teclistamab) with EC authorisation of first-in-class bispecific antibody for the treatment of patients with multiple myeloma. August 24, 2022 press release [accessed 2022 Aug 30]. https://www.jnj.com/janssen-marks-first-approval-worldwide-for-tecvayli-teclistamab-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-multiple-myeloma.
   Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi:10.1056/NEJMoa2203478.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults. September 2, 2022 press release [accessed 2022 Sep 2]. https://www.boehringer-ingelheim.com/human-health/skin-diseases/fda-approves-first-gpp-flare-treatment.
   Google Scholar
• Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–40. doi:10.1056/NEJMoa2111563.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer. October 24, 2022 press release [accessed 2022 Nov 19]. https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html.
   Google Scholar
• AstraZeneca. Imfinzi and Imjudo with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer. November 11, 2022 press release [accessed 2022 Nov 19]. https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html.
   Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y, Dao TV, De Toni EN, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology. 2022;40(4_suppl):379–379. doi:10.1200/JCO.2022.40.4_suppl.379.
   Web of Science ®Google Scholar
• AstraZeneca. Imfinzi and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy. September 11, 2022 press release [accessed 2022 Sep 25]. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html.
   Google Scholar
• Sanofi. European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants. November 4, 2022 press release [accessed 2022 Nov 19]. https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-04-07-00-00-2548492.
   Google Scholar
• Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022 Mar 3;3869:837–46. 10.1056/NEJMoa2110275
   PubMed Web of Science ®Google Scholar
• Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892–94. doi:10.1056/NEJMc2112186.
   PubMed Web of Science ®Google Scholar
• ImmunoGen, Inc. ImmunoGen announces FDA accelerated approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. November 14, 2022 press release [accessed 2022 Nov 19]. https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-fda-accelerated-approval-elaheretm.
   Google Scholar
• ImmunoGen, Inc. ImmunoGen presents additional efficacy and safety analyses evaluating mirvetuximab soravtansine in ovarian cancer at ASCO. May 26, 2022 press release [ accessed 2022 Sept 19]. https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-additional-efficacy-and-safety-analyses.
   Google Scholar
• ImmunoGen, Inc. ImmunoGen presents additional analyses evaluating mirvetuximab soravtansine in ovarian cancer at ESMO. September 11, 2022 press release [ accessed 2022 Sept 19]. https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-additional-analyses-evaluating-mirvetuximab.
   Google Scholar
• Provention Bio, Inc. TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. November 17, 2022 press release [accessed 2022 Nov 19]. https://investors.proventionbio.com/2022-11-17-TZIELD-TM-teplizumab-mzwv-approved-by-FDA-as-the-first-and-only-treatment-indicated-to-delay-the-onset-of-Stage-3-type-1-diabetes-T1D-in-adult-and-pediatric-patients-aged-8-years-and-older-with-Stage-2-T1D.
   Google Scholar
• U.S. Food and Drug Administration. FDA briefing document, Endocrinologic and Metabolic Drugs Advisory Committee Meeting, May 27, 2021: Teplizumab BLA761183. [accessed 2022 Nov 19]. https://www.fda.gov/media/149388/download.
   Google Scholar
• Molecular Targeting Technologies, Inc. Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd announced the Chinese approval for a rabies drug. January 26, 2022 press release [accessed 2022 Sept 19]. https://www.businesswire.com/news/home/20220126005104/en/Molecular-Targeting-Technologies-Inc.-Thomas-Jefferson-University-and-North-China-Pharmaceutical-Co.-Ltd-Announced-the-Chinese-Approval-for-a-Rabies-Drug.
   Google Scholar
• Zhai LL, Wang H, Zhao W, Zhang SF, Miao FM, Cao Y, Chen C, Li YF, Gao J, Lv RY, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022;46:102267. doi:10.1016/j.tmaid.2022.102267.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shi N, Li G, Li L, Bai Y, Yang L, Zhao W, Gao J, Wei J, Zhao W, et al. Population pharmacodynamic analyses of human anti-rabies virus monoclonal antibody (ormutivimab) in healthy adult subjects. Vaccines (Basel). 2022;10(8):1218. doi:10.3390/vaccines10081218.
   PubMed Web of Science ®Google Scholar
• Shanghai Henlius Biotech, Inc. Henlius receives NMPA approval for its first innovative monoclonal antibody HANSIZHUANG. March 25, 2022 press release [ accessed 2022 Sept 19]. https://www.henlius.com/en/NewsDetails-3512-26.html.
   Google Scholar
• Shanghai Henlius Biotech, Inc. Henlius’ novel anti-PD-1 mAb HANSIZHUANG (Serplulimab) receives NMPA approval for the treatment of sqNSCLC. November 1, 2022 press release [accessed 2022 Nov 10]. https://www.henlius.com/en/NewsDetails-3837-26.html.
   Google Scholar
• Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223–32. doi:10.1001/jama.2022.16464.
   PubMed Web of Science ®Google Scholar
• Akeso, Inc. Akeso’s cadonilimab (PD-1/CTLA-4), the first dual immune checkpoint inhibitor to treat cancer, approved for marketing in China. June 29, 2022 press release [accessed 2022 Sept 19]. https://www.akesobio.com/en/media/akeso-news/20220629/.
   Google Scholar
• Zhang J, Huang Y, Xi G, Zhang F. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs. 2020;12(1):1724751. doi:10.1080/19420862.2020.1724751.
   PubMed Web of Science ®Google Scholar
• Biopharma LEPU. Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing by the national medical products administration. July 22, 2022 press release [ accessed 2022 Sept 19]. https://en.lepubiopharma.com/new/187.html.
   Google Scholar
• SinoCellTech Ltd. China Cell’s commercialization process adds new recruits: anpingxi® - Repertuzumab approved for marketing. August 30, 2022 press release [translated from Chinese, accessed 2022 Sept 19]. http://www.sinocelltech.com/Detail/desc/pid/23/sid/363.html.
   Google Scholar
• Shi Y, Zhang Q, Hong X, Wang Z, Gao Y, Zou L, Cen H, Gui L, Li Y, Feng J, et al. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ®) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: a randomized, single-blind, phase III clinical trial. Hematol Oncol. 2022 Jul 20; 10.1002/hon.3054.
   Google Scholar
• Maruho Co., Ltd. Maruho acquires manufacturing and marketing approval in Japan for “Mitchga subcutaneous injection 60mg syringes”, a new treatment targeting itch associated with atopic dermatitis. March 28, 2022 press release [accessed 2022 Sept 19]. https://www.maruho.co.jp/english/information/20220328.html.
   Google Scholar
• Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab JP01 andJP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022;186(4):642–51. doi:10.1111/bjd.20873.
   PubMed Web of Science ®Google Scholar
• Galderma. Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis. June 22, 2022 press release [ accessed 2022 Sept 19]. https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab.
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. Notification of approval to manufacture and market Nanozora® 30mg syringes for S.C. injection, a therapy for rheumatoid arthritis, in Japan: Japan’s first NANOBODY® therapeutic. September 26, 2022 press release [accessed 2022 Nov 10]. https://www.taisho.co.jp/global/news/2022/20220926001109.html.
   Google Scholar
• Takeuchi T, Kawanishi M, Nakanishi M, Yamasaki H, Tanaka Y. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis Rheumatol. 2022;74(11):1776–85. doi:10.1002/art.42273.
   PubMed Web of Science ®Google Scholar
• Genor Biopharma Co., Inc. 1H 2022 Interim results presentation. August 2022 presentation [ accessed 2022 Sept 19]. https://www.genorbio.com/media/1300/1h22-interim-results-presentation.pdf.
   Google Scholar
• An J, Guiling L, Tang J, Li BX, Xiong HH, Qiu H, Luo L, Wang L, Wang D, Zhou Q, et al. Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: results from the phase I dose-escalation and expansion study. J. Clin. Oncol. 2022;40(16_suppl):5526–5526.https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5526.
   Web of Science ®Google Scholar
• Sorrento Therapeutics, Inc. Sorrento’s license partner, Lee’s Pharm, announces full enrollment of 498 patients in a Phase III trial of socazolimab (anti-PD-L1 antibody) for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). May 17, 2022 press release [accessed 2022 Sept 19]. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrentos-license-partner-lees-pharm-announces-full-enrollment.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pipeline highlights as of September 2022. [accessed 2022 Nov 19]. www.hengrui.com/en/pipeline.html.
   Google Scholar
• Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47. doi:10.1016/S1470-2045(22)00224-8.
   PubMed Web of Science ®Google Scholar
• Pharma K. Pipeline. [accessed 2022 Nov 19]. www.kluspharma.com/pipeline.
   Google Scholar
• Sampei Z, Haraya K, Tachibana T, Fukuzawa T, Shida-Kawazoe M, Gan SW, Shimizu Y, Ruike Y, Feng S, Kuramochi T. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One. 2018;13(12):e0209509. doi:10.1371/journal.pone.0209509.
   PubMed Web of Science ®Google Scholar
• Chugai Pharmaceutical Co., Ltd. Anti-C5 recycling antibody crovalimab obtains priority review in China for the treatment of paroxysmal nocturnal hemoglobinuria. August 10, 2022 press release [accessed 2022 Aug 30]. www.chugai-pharm.co.jp/english/news/detail/20220810160000_942.html.
   Google Scholar
• CSPC Pharmaceutical Group Limited. Biologics license application for JMT103 accepted by the NMPA. June 22, 2022 press release [accessed 2022 Aug 30]. https://doc.irasia.com/listco/hk/cspc/announcement/a220622.pdf.
   Google Scholar
• Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q, et al. Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol. 2022 Aug 5;12:971594. 10.3389/fonc.2022.971594 eCollection 2022
   PubMed Web of Science ®Google Scholar
• Niu X, Wei F, Tu C, Huang G, Bi W, Li J, Yao W, Zhang X, Shen J, Zhang G, et al. Efficacy and safety of JMT103 in patients with giant cell tumor of bone: a multicenter, single-arm, open-label, phase Ib/II study. J Clin Oncol. 2021;39(15_suppl):11526. doi:10.1200/JCO.2021.39.15_suppl.11526.
   Google Scholar
• Innovent Biologics, Inc. Innovent announces the NMPA acceptance of the new drug application for tafolecimab injection (anti-PCSK-9 antibody). June 14, 2022 press release [accessed 2022 Aug 30]. https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=332.
   Google Scholar
• Innovent Biologics, Inc. Innovent announces two registration studies of IBI306 (anti-PCSK-9 antibody) met primary endpoint. February 17, 2022 press release [accessed 2022 Aug 30]. https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=306.
   Google Scholar
• Innovent Biologics, Inc. Innovent releases results of a Phase 3 clinical study of IBI306 (PCSK-9 inhibitor) in Chinese patients with heterozygous familial hypercholesterolemia at the American College of Cardiology Annual Congress 2022. April 4, 2022 press release [accessed 2022 Sept 19]. https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=314.
   Google Scholar
• Pharma Japan. Novo seeks Japan approval of hemophilia drug concizumab. August 31, 2022 business news [accessed 2022 Nov 25]. https://pj.jiho.jp/article/247369.
   Google Scholar
• Jiménez-Yuste V, Angchaisuksiri P, Castaman G, Cepo K, Haaning J, Jacobsen S, Mahlangu J, Matsushita T, Nogami K, Shapiro A Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the Phase 3 explorer7 trial. Abstract Number: LB 01.2; International Society on Thrombosis and Haemostasis, London, UK; July 9-13, 2022. [accessed 2022 July 9-13]. https://abstracts.isth.org/abstract/concizumab-prophylaxis-in-patients-with-haemophilia-a-or-b-with-inhibitors-efficacy-and-safety-results-from-the-primary-analysis-of-the-phase-3-explorer7-trial/.
   Google Scholar
• Coherus BioSciences, Inc., Shanghai Junshi Biosciences Co., Ltd. Coherus and Junshi Biosciences announce FDA acceptance of resubmission of BLA for toripalimab for the treatment of nasopharyngeal carcinoma. July 6, 2022 press release [accessed 2022 Oct 15]. https://investors.coherus.com/news-releases/news-release-details/coherus-and-junshi-biosciences-announce-fda-acceptance.
   Google Scholar
• Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536–43. doi:10.1038/s41591-021-01444-0.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns. June 1, 2022 FDA Drug Safety Communication [accessed 2022 Oct 15]. https://www.fda.gov/media/158834/download.
   Google Scholar
• TG Therapeutics Inc. TG Therapeutics announces FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS. May 31, 2022 press release [accessed 2022 Oct 15]. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-extension-bla-pdufa-date.
   Google Scholar
• Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–14. doi:10.1056/NEJMoa2201904.
   PubMed Web of Science ®Google Scholar
• Eisai Co., Ltd., Biogen, Inc. The U.S. FDA accepts and grants priority review For Eisai’s biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway. July 6, 2022 press release [accessed 2022 Oct 15]. https://www.eisai.com/news/2022/news202254.html.
   Google Scholar
• Eisai Co., Ltd., Biogen, Inc. Lecanemab confirmatory Phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer’s disease. September 27, 2022 press release [accessed 2022 Oct 15]. https://investors.biogen.com/news-releases/news-release-details/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary.
   Google Scholar
• Byondis. Byondis and medac enter into license and collaboration and supply agreements for anti-HER2 ADC trastuzumab duocarmazine (SYD985). May 3, 2022 press release [ accessed 2022 Sept 19]. https://www.byondis.com/media/press-releases/byondis-and-medac-enter-into-license-and-collaboration-and-supply-agreements-for-anti-her2-adc-trastuzumab-duocarmazine.
   Google Scholar
• Byondis. FDA accepts Byondis’ biologics license application for [vic-]trastuzumab duocarmazine (SYD985) in HER2-positive metastatic breast cancer. July 12, 2022 press release [ accessed 2022 Sept 19]. https://www.byondis.com/media/press-releases/fda-accepts-byondis-biologics-license-application-for-vic-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer.
   Google Scholar
• Byondis. EMA validates marketing authorization application for trastuzumab duocarmazine (SYD985) in HER2-positive metastatic breast cancer. July 18, 2022 press release [ accessed 2022 Sept 19]. https://www.byondis.com/media/press-releases/ema-validates-marketing-authorization-application-for-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer.
   Google Scholar
• Eli Lilly and Company. Nearly two-thirds of patients respond to mirikizumab treatment at 12 weeks in Lilly’s first-in-class ulcerative colitis Phase 3 LUCENT-1 study. February 18, 2022 press release [accessed 2022 Sep 25]. https://investor.lilly.com/news-releases/news-release-details/nearly-two-thirds-patients-respond-mirikizumab-treatment-12.
   Google Scholar
• Eli Lilly and Company. Fifty percent of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in Lilly’s pivotal Phase 3 study. May 24, 2022 press release [accessed 2022 Sep 25]. https://investor.lilly.com/news-releases/news-release-details/fifty-percent-patients-ulcerative-colitis-treated-mirikizumab.
   Google Scholar
• Genentech. New pivotal data demonstrate clinical benefit of Genentech’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma. May 26, 2022 press release [ accessed 2022 Sept 19]. https://www.gene.com/media/press-releases/14954/2022-05-26/new-pivotal-data-demonstrate-clinical-be.
   Google Scholar
• Huang Z, Pang X, Zhong T, Qu T, Chen N, Ma S, He X, Xia D, Wang M, Xia M, et al. Penpulimab, an Fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events. Front Immunol. 2022;13:924542. doi:10.3389/fimmu.2022.924542.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Lilly reports second-quarter financial results, highlights momentum of new medicines and pipeline advancements. August 4, 2022 press release [accessed 2022 Oct 15]. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-financial-results-highlights.
   Google Scholar
• Eli Lilly and Company. Lilly’s donanemab slows clinical decline of Alzheimer’s disease in positive Phase 2 trial. January 11, 2021 press release [accessed 2022 Oct 15]. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-slows-clinical-decline-alzheimers-disease.
   Google Scholar
• Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022;79(10):1015–24. doi:10.1001/jamaneurol.2022.2793.
   PubMed Web of Science ®Google Scholar
• Almirall SA Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis. October 28, 2022 press release [accessed 2022 Nov 25]. https://www.almirall.com/newsroom/news/almirall-announces-ema-acceptance-for-filing-of-marketing-authorization-application-maa-for-lebrikizumab-in-atopic-dermatitis.
   Google Scholar
• Almirall SA. Almirall: eight out of ten patients maintained skin clearance at one year in lebrikizumab atopic dermatitis monotherapy trials. June 7, 2022 press release [accessed 2022 Sep 25]. https://www.almirall.com/newsroom/news/almirall-eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lebrikizumab-atopic-dermatitis-monotherapy-trials-1.
   Google Scholar
• Genmab, Inc. Genmab announces U.S. Food and Drug Administration accepts for priority review biologics license application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma (LBCL). 2022 Nov 21 press release [accessed 2022 Nov 21]. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-us-food-and-drug-administration-accepts.
   Google Scholar
• Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–69. doi:10.1016/S0140-6736(21)00889-8.
   PubMed Web of Science ®Google Scholar
• AbbVie, Inc. AbbVie announces late-breaking results from Phase 2 trial of investigational epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory large B-cell lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress. June 11, 2022 Press Release [accessed 2022 Sep 25]. https://news.abbvie.com/news/press-releases/abbvie-announces-late-breaking-results-from-phase-2-trial-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl-at-european-hematology-association-eha-annual-congress.htm.
   Google Scholar
• BeiGene LTD BeiGene announces acceptance of 11th regulatory submission for PD-1 inhibitor tislelizumab in China. August 23, 2022 press release [accessed 2022 Sep 25]. https://ir.beigene.com/news/beigene-announces-acceptance-of-11th-regulatory-submission-for-pd-1-inhibitor-tislelizumab-in-china/2c7d63b6-7abe-441b-b23d-8d850c8f7ba4/.
   Google Scholar
• BeiGene LTD BeiGene provides regulatory update on the U.S. biologics license application (BLA) for PD-1 inhibitor tislelizumab in 2L ESCC. July 14, 2022 press release [accessed 2022 Sep 25]. https://ir.beigene.com/news/beigene-provides-regulatory-update-on-the-u-s-biologics-license-application-bla-for-pd-1-inhibitor-tislelizumab/09127f95-fd94-4a1b-b215-3e356e5fcfd9/.
   Google Scholar
• Novartis. Novartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancers. April 6, 2022 press release [accessed 2022 Sep 25]. https://www.novartis.com/news/media-releases/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancers.
   Google Scholar
• Shen L, Kato K, Kim S-B, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase iii study. J Clin Oncol. 2022 Sep 10;40(26):3065–76. 10.1200/JCO.21.01926
   PubMed Web of Science ®Google Scholar
• BeiGene LTD Results from RATIONALE 303: a global Phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. BeiGene presentation [accessed 2022 Oct 5]. https://www.beigenemedical.com/CongressDocuments/Zhou_BGB-A317-303_AACR_presentation_2021.pdf.
   Google Scholar
• Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a Randomized Phase 3 Trial. J Thorac Oncol. 2021;16(9):1512–22. doi:10.1016/j.jtho.2021.05.005.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(5):709–17. doi:10.1001/jamaoncol.2021.0366.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting, June 24, 2021: BLA 761209 – retifanlimab. [accessed 2022 Sep 25]. https://www.fda.gov/media/150325/download.
   Google Scholar
• Incyte Corporation. Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal (SCAC). July 23, 2021 press release [accessed 2022 Sep 25]. https://investor.incyte.com/news-releases/news-release-details/incyte-provides-regulatory-update-retifanlimab-treatment-certain.
   Google Scholar
• Rao S, Jones M, Bowman J, Tian C, Spano JP. POD1UM-303/InterAACT 2: a phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol. 2022;12:935383. doi:10.3389/fonc.2022.935383.
   PubMed Web of Science ®Google Scholar
• Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation–associated thrombotic microangiopathy. J Clin Oncol. 2022;40(22):2447–57. doi:10.1200/JCO.21.02389.
   PubMed Web of Science ®Google Scholar
• Omeros Corporation. Omeros Corporation receives decision from FDA on formal dispute resolution request for narsoplimab. November 8, 2022 press release [accessed 2022 Nov 10]. https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-receives-decision-fda-formal-dispute.
   Google Scholar
• Innovent Biologics, Inc., Eli Lilly and Company. BLA761222 ODAC - Sintilimab BLA in non-squamous NSCLC. February 10, 2022 presentation [accessed 2022 Oct 15]. https://www.fda.gov/media/156090/download.
   Google Scholar
• Eli Lilly and Company. Lilly announces complete response letter for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer. March 24, 2022 press release [2022 Sep 25]. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination.
   Google Scholar
• Y-mAbs Therapeutics, Inc. Y-mAbs announces pivotal data for omburtamab. October 3, 2022 press release [accessed 2022 Oct 15]. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-pivotal-data-omburtamab.
   Google Scholar
• Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022;14(1):2123299. doi:10.1080/19420862.2022.2123299.
   PubMed Web of Science ®Google Scholar
• PhaseBio Pharmaceuticals, Inc. PhaseBio Pharmaceuticals reports second quarter 2022 financial results and recent business highlights. August 12, 2022 press release [accessed 2022 Sep 25]. https://investors.phasebio.com/news-releases/news-release-details/phasebio-pharmaceuticals-reports-second-quarter-2022-financial.
   Google Scholar
• Bhatt DL, Pollack CV, Mazer CD, Angiolillo DJ, Steg PG, James SK, Weitz JI, Ramnath R, Arnold SE, Mays MC, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evid. 2022;1(3):3. doi:10.1056/EVIDoa2100047.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron corporate presentation. August 2022 [accessed 2022 Sep 25]. https://investor.regeneron.com/static-files/2bed4561-b43f-4fe6-be95-021f223cd7cb.
   Google Scholar
• CSL Limited. CSL announces positive top-line Phase 3 results for garadacimab as preventive treatment in patients with hereditary angioedema (HAE). August 17, 2022 press release [accessed 2022 Sep 25]. https://www.csl.com/news/2022/20220817-csl-announces-positive-results-for-garadacimab.
   Google Scholar
• McKenzie A, Roberts A, Malandkar S, Feuersenger H, Panousis C, Pawaskar D. A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab. Clin Transl Sci. 2022;15(3):626–37. doi:10.1111/cts.13180.
   PubMed Web of Science ®Google Scholar
• Wong KL, Li Z, Ma F, Wang D, Song N, Chong CH, Luk KK, Leung SO. SM03, an anti-CD22 antibody, converts cis-to-trans ligand binding of CD22 against α2,6-linked sialic acid glycans and immunomodulates systemic autoimmune diseases. J Immunol. 2022 Jun 15;208(12):2726–37. doi:10.4049/jimmunol.2100820
   PubMed Web of Science ®Google Scholar
• SinoMab BioScience Limited. Interim report 2022. [accessed 2022 Oct 15]. https://files.services/files/517/2022/0927/20220927164502_35278113_en.pdf
   Google Scholar
• Li J, Li M, Wu D, Zhou J, Leung S-O, Zhang F. SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 5;61(5):1841–48. doi:10.1093/rheumatology/keab699.
   PubMed Web of Science ®Google Scholar
• Kodiak Sciences Inc. Kodiak Sciences announces second quarter 2022 financial results and recent business highlights. August 9, 2022 press release [accessed 2022 Nov 10]. https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-second-quarter-2022-financial-results.
   Google Scholar
• Kodiak Sciences Inc. Corporate presentation, August 2022. [accessed 2022 Nov 19]. https://ir.kodiak.com/static-files/687f81e2-520a-4b6e-a91b-cc06da614bb4.
   Google Scholar
• Kodiak Sciences Inc. KSI-301 anti-VEGF antibody biopolymer conjugate for retinal vein occlusion: primary 24-week efficacy and safety outcomes of the beacon phase 3 pivotal study, September 30, 2022 presentation. [accessed 2022 Sep 25]. https://ir.kodiak.com/static-files/f3a30a82-ed03-4313-acb1-73f22e2a0c4b.
   Google Scholar
• Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals reports third quarter 2022 financial results and provides clinical and business update. November 3, 2022 pess release [accessed 2022 Nov 10]. https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-third-quarter-2022-financial.
   Google Scholar
• Innovent Biologics, Inc. Innovent 2022 interim results, August 2022. [accessed 2022 Oct 31]. https://img.innoventbio.com/file1.pdf.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron corporate presentation, August 2022. [accessed 2022 Oct 15]. https://investor.regeneron.com/static-files/2bed4561-b43f-4fe6-be95-021f223cd7cb.
   Google Scholar
• Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O’Brien SM, Chávez JC, Duell J, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–e339. doi:10.1016/S2352-3026(22)00072-2.
   PubMed Web of Science ®Google Scholar
• Checkpoint Therapeutics, Inc. Checkpoint Therapeutics corporate presentation September 2022. [accessed 2022 Sep 25]. https://ir.checkpointtx.com/company-information/presentations.
   Google Scholar
• Checkpoint Therapeutics, Inc. Checkpoint Therapeutics reports second quarter 2022 financial results and recent corporate highlights. August 12, 2022 press release [accessed 2022 Sep 25]. https://ir.checkpointtx.com/news-events/press-releases/detail/87/checkpoint-therapeutics-reports-second-quarter-2022.
   Google Scholar
• Actinium Pharmaceuticals, Inc. Actinium Investor Presentation September 2022. [accessed 2022 Sep 25]. https://d1io3yog0oux5.cloudfront.net/_f3b741a645f0b39c25728ef872153297/actiniumpharma/db/206/944/pdf/Actinium_Investor+Presentation_September+2022.pdf
   Google Scholar
• Actinium Pharmaceuticals, Inc. Actinium announces positive top-line results from pivotal Phase 3 SIERRA trial of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. October 31, 2022 press release [accessed 2022 Oct 31]. https://ir.actiniumpharma.com/press-releases/detail/428/actinium-announces-positive-top-line-results-from-pivotal.
   Google Scholar
• Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. announces 82% of control arm patients did not receive a bone marrow transplant by conventional means but 100% of patients who received Iomab-B, including crossover patients, in the Phase 3 SIERRA trial successfully engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR. April 25, 2022 press release [accessed 2022 Sep 25]. https://ir.actiniumpharma.com/press-releases/detail/421/actinium-pharmaceuticals-inc-announces-82-of-control-arm.
   Google Scholar
• AstraZeneca. Clinical trials appendix H1 2022 results update [accessed 2022 Sep 25]. https://www.astrazeneca.com/content/dam/az/PDF/2022/h1-2022/H1-2022-results-clinical-trials-appendix.pdf.
   Google Scholar
• Astellas Pharma, Inc. Integrated report 2022 for the year ending March 31, 2022. [accessed 2022 October 5]. https://www.astellas.com/en/system/files/astellas_ir2022_en_20221004.pdf.
   Google Scholar
• Astellas Pharma, Inc. Astellas announces zolbetuximab meets primary endpoint in Phase 3 SPOTLIGHT trial as first-line treatment in Claudin 18.2 positive, HER2-negative locally advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers. November 17, 2022 press release [accessed 2022 Nov 17]. https://www.astellas.com/en/news/26821.
   Google Scholar
• Elevar Therapeutics, Inc. Elevar Therapeutics announces positive pre-NDA meeting for rivoceranib combination with camrelizumab as hepatocellular carcinoma treatment option. October 11, 2022 press release [accessed 2022 Oct 31]. https://elevartherapeutics.com/2022/10/11/elevar-therapeutics-announces-positive-pre-nda-meeting-for-rivoceranib-combination-with-camrelizumab-as-hepatocellular-carcinoma-treatment-option/.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. Camrelizumab in combination with rivoceranib (apatinib) significantly prolonged overall survival and progression-free survival vs sorafenib in patients with unresectable hepatocellular carcinoma in a multinational Phase 3 trial, a joint program with Elevar Therapeutics. September 10, 2022 press release [2022 Oct 31]. https://www.hengrui.com/en/media/detail-254.html.
   Google Scholar
• CStone Pharmaceuticals. CStone Pharmaceuticals reports 2022 interim results and business updates. August 25, 2022 press release [accessed 2022 Oct 31]. https://www.cstonepharma.com/en/html/news/2808.html.
   Google Scholar
• Huang H, Tao R, Yang Y, Cen H, Zhou H, Guo Y, Zou L, Cao J, Huang Y, Jin J, et al. GEMSTONE-201: preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL). J Clin Oncol. 2022;40(16):7501–7501. doi:10.1200/JCO.2022.40.16_suppl.7501.
   Web of Science ®Google Scholar
• I-Mab Biopharma. I-Mab partner MorphoSys announces new license agreements for felzartamab and TJ210. June 15, 2022 press release [accessed 2022 Sep 25]. https://ir.i-mabbiopharma.com/news-releases/news-release-details/i-mab-partner-morphosys-announces-new-license-agreements.
   Google Scholar
• I-Mab Biopharma. Pioneering the Next-Generation of Immuno-Oncology. October 2022 corporate presentation [accessed 2022 Nov 25]. https://ir.i-mabbiopharma.com/system/files-encrypted/nasdaq_kms/assets/2022/10/19/7-56-59/Corporate%20Presentation_Oct%202022_v2.pdf.
   Google Scholar
• Sanofi. Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China. August 4, 2022 press release [accessed 2022 Sep 25]. https://www.sanofi.com/en/media-room/press-releases/2022/2022-08-04-15-30-00-2492626.
   Google Scholar
• Sanofi. Sanofi Q2 2022 results. July 28, 2022 presentation. [accessed 2022 Sep 25]. www.sanofi.com/dam/jcr:2c6b06a7-37bd-4a6a-b243-3ac5cee2752c/2022_07_28_Sanofi_Q2_2022_Results.pdf
   Google Scholar
• Roche Group. Roche YTD September 2022 sales. October 18, 2022 presentation with appendix [accessed 2022 Nov 10]. https://www.roche.com/investors/events/q3-2022.
   Google Scholar
• Roche Group. Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. May 11, 2022 Roche press release [accessed 26 Sep 2022]. https://www.roche.com/media/releases/med-cor-2022-05-11.
   Google Scholar
• Pfizer Inc. Pfizer’s elranatamab granted FDA Breakthrough Therapy designation for relapsed or refractory multiple myeloma. November 3, 2022 press release [accessed 2022 Nov 10]. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy.
   Google Scholar
• Pfizer Inc. Second quarter 2022 earnings teleconference. July 28, 2022 [accessed 2022 Sep 25]. https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf.
   Google Scholar
• CStone Pharmaceuticals. Investor presentation, July 2022. [accessed 2022 Sep 25]. https://www.cstonepharma.com/en/uploads/2022/07/165846866935356.pdf.
   Google Scholar
• Shen L, Guo Y, Zhang Y, Li W, Gong J, Li Q, Ma Z, Wang N, Su R, Cai Z, et al. Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC). Journal of Clinical Oncology. (June 01, 2022);40(16_suppl):e16191–e16191. 10.1200/JCO.2022.40.16_suppl.e16191
   Web of Science ®Google Scholar
• Alphamab Oncology. The first interim analysis of KN046 Phase III trial successfully reached prespecified PFS endpoint. March 31, 2022 press release [accessed 2022 Sep 25]. https://www.alphamabonc.com/en/html/news/2414.html.
   Google Scholar
• Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, Yang S, Liu Y, Wang N, Huang Y, et al. Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: an open-label, multi-center phase II trial. European Society for Medical Oncology Congress, September 10, 2022, Paris, France. Poster session 14; abstract 1029P. [accessed 2022 Sep 25]. https://oncologypro.esmo.org/meeting-resources/esmo-congress/two-year-follow-up-from-kn046-in-combination-with-platinum-doublet-chemotherapy-as-first-line-1l-treatment-for-nsclc-an-open-label-multi-center.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron corporate presentation, August 2022. [accessed 2022 Sep 25]. https://investor.regeneron.com/static-files/2bed4561-b43f-4fe6-be95-021f223cd7cb.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. New REGN5458 (BCMAXCD3) Phase 1 data show 75% response rate at highest dose levels studied in patients with heavily pretreated multiple myeloma. December 11, 2021 press release [accessed 2022 Sep 25]. https://newsroom.regeneron.com/news-releases/news-release-details/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-highest.
   Google Scholar
• Jazz Pharmaceuticals plc. Jazz Pharmaceuticals and Zymeworks announce exclusive license agreement to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody. October 19, 2022 press release [accessed 2022 Oct 31]. http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license.
   Google Scholar
• Zymeworks, Inc. Zymeworks reports last patient enrolled in pivotal study of zanidatamab in treatment of HER2-expressing late-line biliary tract cancer. April 28, 2022 press release [accessed 2022 Sep 25]. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-reports-last-patient-enrolled-pivotal-study.
   Google Scholar
• Zymeworks, Inc. Corporate presentation, September 2022. [accessed 2022 Oct 31]. https://ir.zymeworks.com/static-files/efbb3a4f-99d3-4eb2-9c9f-681abd2e1b6c.
   Google Scholar
• Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, et al. HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18. doi:10.2217/fon-2022-0595.
   Web of Science ®Google Scholar
• The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen announces U.S. FDA Breakthrough Therapy designation granted for talquetamab for the treatment of relapsed or refractory multiple myeloma. June 29, 2022 press release [accessed 2022 Nov 17]. https://www.janssen.com/us/sites/www_janssen_com_usa/files/janssen_announces_us_fda_breakthrough_therapy_designation_granted_for_talquetamab_for_the_treatment_of_relapsed_or_refractory_multiple_myeloma.pdf.
   Google Scholar
• Minnema MC, Krishnan A, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Mateos M-V, Costa LJ, Caers J, et al. Talquetamab, a G protein-coupled receptor family C Group 5 member D x CD3 bispecific antibody, in relapsed/refractory multiple myeloma: updated efficacy and safety results from MONUMENTAL-1. Abstract release date: 05/26/22 EHA Library [accessed 2022 Nov 17]. https://library.ehaweb.org/eha/2022/eha2022-congress/357046/monique.c.minnema.talquetamab.a.g.protein-coupled.receptor.family.c.group.5.html.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron reports third quarter 2022 financial and operating results. November 3, 2022 press release [accessed 2022 Nov 17]. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating.
   Google Scholar
• Nordic Nanovector ASA and APIM Therapeutics. Nordic Nanovector and APIM Therapeutics announce merger agreement. November 9, 2022 press release [accessed 2022 Nov 19]. https://www.prnewswire.com/news-releases/nordic-nanovector-and-apim-therapeutics-announce-merger-agreement-301673852.html.
   Google Scholar
• Ambrx Biopharma Inc. Ambrx Biopharma Inc. announces strategic reprioritization and provides corporate update. October 18, 2022 press release [accessed 2022 Nov 17]. https://ir.ambrx.com/news/news-details/2022/Ambrx-Biopharma-Inc.-Announces-Strategic-Reprioritization-and-Provides-Corporate-Update/default.aspx.
   Google Scholar
• Roche. Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease. November 14, 2022 press release [accessed 2022 Nov 19]. https://www.roche.com/media/releases/med-cor-2022-11-14
   Google Scholar
• Sesen Bio, Inc., Carisma Therapeutics Inc. Sesen Bio and Carisma Therapeutics announce merger agreement. September 21, 2022 press release [accessed 2022 Nov 19]. https://carismatx.com/sesen-bio-and-carisma-therapeutics-announce-merger-agreement/
   Google Scholar
• Carlo-Stella C, Ansell S, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett N, Bence-Bruckler I, et al. Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (r/r CHL). European Hematology Association Hybrid Congress, June 10, 2022, Vienna (Austria). https://library.ehaweb.org/eha/2022/eha2022-congress/357065/carmelo.carlo-stella.camidanlumab.tesirine.updated.efficacy.and.safety.in.an.html.
   Google Scholar
• ADC Therapeutics SA. ADC Therapeutics reports third quarter 2022 financial results and provides business updates. November 8, 2022 press release [accessed 2022 Nov 19]. https://ir.adctherapeutics.com/press-releases/press-release-details/2022/ADC-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates/default.aspx.
   Google Scholar
• Fashoyin-Aje LA, Mehta GU, Beaver JA, Pazdur R. The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022;387(16):1439–42. doi:10.1056/NEJMp2208954.
   PubMed Web of Science ®Google Scholar
• GSK. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization. November 22, 2022 press release [accessed 2022 Nov 22]. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/
   Google Scholar